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Abstract
Background: Human umbilical mesenchymal stem cells (HUMSCs) isolated from Wharton’s jelly of the umbilical cord can be
easily obtained and processed compared with embryonic or bone marrow stem cells. These cells may be a valuable source
in the repair of spinal cord injury.
Methodology/Principal Findings: We examine the effects of HUMSC transplantation after complete spinal cord transection
in rats. Approximately 5610
5 HUMSCs were transplanted into the lesion site. Three groups of rats were implanted with
either untreated HUMSCs (referred to as the stem cell group), or HUMSCs treated with neuronal conditioned medium (NCM)
for either three days or six days (referred to as NCM-3 and NCM-6 days, respectively). The control group received no HUMSCs
in the transected spinal cord. Three weeks after transplantation, significant improvements in locomotion were observed in
all the three groups receiving HUMSCs (stem cell, NCM-3 and NCM-6 days groups). This recovery was accompanied by
increased numbers of regenerated axons in the corticospinal tract and neurofilament-positive fibers around the lesion site.
There were fewer microglia and reactive astrocytes in both the rostral and caudal stumps of the spinal cord in the stem cell
group than in the control group. Transplanted HUMSCs survived for 16 weeks and produced large amounts of human
neutrophil-activating protein-2, neurotrophin-3, basic fibroblast growth factor, glucocorticoid induced tumor necrosis factor
receptor, and vascular endothelial growth factor receptor 3 in the host spinal cord, which may help spinal cord repair.
Conclusions/Significance: Transplantation of HUMSCs is beneficial to wound healing after spinal cord injury in rats.
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Introduction
Mammalian spinal cord injury is followed by the degeneration
of axons, loss of neurons and glia, and demyelination around the
lesion site. Axonal regeneration in the central nervous system
(CNS) is impeded partly by myelin-associated inhibitors [1–2] and
formation of a post-lesion scar barrier [3]. The extent of intrinsic
cell renewal alone [4], even after application of mitogenic agents
such as epidermal growth factor and fibroblast growth factor-2
[5,6], is not sufficient to allow substantial recovery following spinal
cord injury [7]. Therefore, therapeutic strategies that involve
exogenous cell replacement have to be considered.
Mesenchymal cells from Wharton’s jelly of the umbilical cord
possess stem cell properties [8–10]. We previously demonstrated
that human umbilical mesenchymal stem cells (HUMSCs) could
be induced to differentiate into neuron-like cells (about 87%),
express neurofilament and functional mRNAs responsible for the
syntheses of subunits of the kainate receptor and glutamate
decarboxylase, and generate an inward current in response to
evocation by glutamate [9]. HUMSCs are also capable of
differentiating into osteogenic, chondrogenic, adipogenic, and
myogenic cells in vitro [10]. We also found that the transformed
HUMSCs in the striatum were still viable 4 months after
transplantation without the need for immunological suppression,
suggesting that HUMSCs might be a good stem cell source for
transplantation [11].
In this study, we evaluate the effect of transplantation of
HUMSCs on axon regeneration in the injured spinal cord using a
complete transection model in rats. Cultures of HUMSCs were
treated with neuronal conditioned medium (NCM) for 0, 3 or 6
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rostral and caudal stumps of the transected spinal cords. The
purpose of this study is to examine whether the implanted
HUMSCs can induce the regeneration of descending nerve fibres
and promote the recovery of hind-limb movement of the spinal
cord-injured rats.
Results
HUMSC transplantation promotes the regrowth of the
injured corticospinal fibers to cross the lesion site
Cultured HUMSCs were transplanted into the transected spinal
cord (Fig. 1) as described in more details in the Materials and
Methods. In order to trace whether the axons in the corticospinal
tract had passed the transected lesion site, the tracer biotinylated
dextran amine (BDA) was injected into the sensorimotor cortex of
the rats 16 weeks after the surgery. The results showed that there
were BDA-positive dots in the rostral stump, but not in the caudal
stump, of the transected spinal cord in the control group (Fig. 2A,
B). This implies that in the control group, the corticospinal fibers
had not grown through the transected site. In the three
transplanted groups (stem cell, NCM-3, and NCM-6 days groups),
both rostral and caudal stumps of the spinal cord had patches of
BDA-positive fibers (Fig. 2C–H). These BDA-positive fibers
extended up to 1 cm caudal to the implanted site. However, the
number of BDA-positive fibers which had extended through the
transection to the caudal stumps was significantly lower than the
number at the rostral stumps.
HUMSC transplantation promotes regeneration and
provides neuroprotection around the lesion site
Sixteen weeks after transection, the neurofilament-positive fibers
at the lesion site were scarce in the control group (Fig. 3A–C).
Quantification was performed in spinal sections obtained from the
transection site. The average number and total length of
neurofilament-positive axons in the control group were
193.6635.3/mm
2 and 2839.16802.1 mm/mm
2 (Fig 3M, N). In
the three transplanted groups, the neurofilament-positive fibers at
the lesion site were prominently labelled (Fig. 3D–L). In the stem
cell group, the average numbers and total length were
882.3630.1/mm
2 and 10184.46669.8 mm/mm
2, which were
statistically greater compared to those of the control group
(p,0.05) (Fig. 3M, N). The NCM-3 and NCM-6 days groups
displayed significantly higher numbers of axons when compared
with the control group (Fig. 3M, N). However, the NCM-3 and
NCM-6 days groups displayed significantly lower numbers of
axons when compared with the stem cell group (Fig. 3M, N).
HUMSC grafts change the distribution of astrocytes in
spinal cords
Anti-glial fibrillary acidic protein (GFAP) immunostaining was
performed to assess the distribution of astrocytes 16 weeks after
transection. In the control group, astrocytes in the lesion site were
scarce (Fig. 4A, C). However, a large number of astrocytes were
found at the rostral and caudal stumps. These astrocytes were
packed tightly together as a scar barrier (Fig. 4A, B). In the stem
cell group, there were a few astrocytes in the lesion site (Fig. 4D,
F). There were still many astrocytes at the rostral and caudal
stumps, but they appeared to be permissive and did not form a
prominent glial limitans to completely block regenerative axons
(Fig. 4D, E).
HUMSC grafts reduce the activation of microglia in spinal
cords
Anti-ED1 immunostaining was performed to assess the
activation of microglia. In the control group, there were some
activated microglia in the lesion site (Fig. 4G, H). Large numbers
of activated microglia appeared in the rostral and caudal stumps
(Fig. 4G, I). In the stem cell group, there were some activated
microglia in the lesion site (Fig. 4J, K). There were fewer activated
microglia in the rostral and caudal stumps in the stem cell group
(Fig. 4J, L), compared to those of the control group.
Transplanted HUMSCs survive and migrate in the host
spinal cord
Anti-human specific nuclear antigenimmunostainingwas used to
trace the survival and migration pattern of the HUMSCs. In all
three transplanted groups (stem cell, NCM-3, and NCM-6 days
groups), HUMSCs survived around the implantation sites at the
rostral stump, transection site, and caudal stump (Fig. 5A–J). A
series of sections showed that large numbers of HUMSCs survived
at least for 4 months after transplantation. The HUMSCs had
migrated from the implantation site for about 1.5 mm in the caudal
direction of the rostrocaudal axis. The distribution and migration
patterns of the implanted HUMSCs in the three transplanted
groups did not show apparent differences (Fig. 5K–M).
Untreated HUMSCs remain undifferentiated in the host
spinal cord
Double-staining of human-specific nuclear antigen and neuro-
filament revealed that most untreated HUMSCs did not
differentiate into neurons (Fig. 6A). Staining with anti-human
specific nuclear antigen and anti-GFAP showed that the majority
of untreated HUMSCs had not differentiated into astrocytes
(Fig. 6B). Double-staining of human-specific nuclear antigen and
myelin basic protein (MBP) indicated that most untreated
HUMSCs were MBP-negative cells, suggesting these cells did
not differentiate into oligodendrocytes (Fig. 6C).
Transplanted HUMSCs express human cytokines and
growth factors in the transected rat spinal cord
Spinal cord protein from the rats of control, stem cell, NCM-3
days, NCM-6 days groups were prepared and incubated with
membranes containing an array of 174 human protein cytokine
antibodies. Autoradiographs were scanned, and the density of each
cytokine at the corresponding position was determined. The
relative intensities of each cytokine were normalized to control
Figure 1. Experimental design for cell grafting after the
transection of the spinal cord at the 8th thoracic level.
doi:10.1371/journal.pone.0003336.g001
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protein-2 (NAP-2), neurotrophin-3 (NT-3), and vascular endothe-
lial growth factor receptor 3 (VEGF R3) were significantly
increased in the rat spinal cord of the stem cell, NCM-3 and
NCM-6 days groups (p,0.05) (Fig 6D). The expression of human
basic fibroblast growth factor (bFGF) and glucocorticoid induced
tumor necrosis factor receptor family (GITR) in the stem cell
group were higher than those in the other three groups (control,
NCM-3 and NCM-6 days) (p,0.05) (Fig 6D).
HUMSC transplantation improves locomotion recovery
Behavioral testing was performed weekly until 16 weeks post-
lesion. No significant improvement was seen during the period of
16 weeks after injury in the control group. Their Basso-Beattie-
Bresnahan (BBB) locomotor scores ranged between 0 and 2 points
(Fig. 6E, Table 1, and Video S1). Three weeks after transplan-
tation, the first signs of recovery in locomotor function were
observed and were statistically significant between the tranplanted
groups and the control group. In the stem cell group, BBB scores
rose to 6–8 by week 7. This was significantly better than the NCM-
3 and NCM-6 days groups (p,0.05, Fig. 6E and Table 1). This
trend continued up to 16 weeks. Rats in the stem cell group were
able to coordinate movement between the forelimbs and the three
joints of the hind-limbs to achieve a walk. Their hind-limbs were
also able to lift their bodies off the ground for brief periods, but
were unable to support their body weight while walking (Fig. 6E,
Table 1, and Video S2).
Discussion
Our study provides evidence that transplantation of human
umbilical mesenchymal stem cells from Wharton’s jelly is an
effective strategy to promote the regeneration of corticospinal fibers
and locomotor recovery after spinal cord transection in the rat.
Ideal donor cells for neurological disease therapy should be (i)
easily available; (ii) capable of rapid expansion in culture; (iii)
immunologically compatible; (iv) capable of long-term survival and
integration in the host tissue, and (v) amenable to stable
transfection and long-term expression of exogenous genes [12].
HUMSCs in Wharton’s jelly of the umbilical cord can be easily
obtained and processed, compared to embryonic or bone marrow
stem cells. In the present study, approximately 1610
6 HUMSCs
were collected from a 20 cm-umbilical cord. The number of
HUMSCs doubled (2610
6) in 10% fetal bovine serum (FBS)-
Dulbecco’s Modified Eagle Medium (DMEM) in 3 days. In our
previous studies, we found that the transformed HUMSCs in the
striatum were still viable 4 months after transplantation without
the need for immunological suppression [11]. Moreover, trans-
formed HUMSCs survived in the rat liver and were able to control
Type 1 Diabetes [13]. Likewise, the HUMSCs in the present study
survived in rat spinal cords, suggesting that HUMSCs are an ideal
stem cell source for transplantation.
We have demonstrated in vitro that approximately 59% of
HUMSCs differentiate into neuronal progenitor cells with prolifer-
ative ability after 3 days of treatment with NCM, whereas 87% of
HUMSCs become immature neurons after 6 days of NCM
treatment [9]. Here, the majority of the implanted, untreated
HUMSCs in the transected spinal cord remained undifferentiated
(Fig. 6A–C). This result contrasts to previous research which
demonstrated that embryonic stem cells differentiate into oligoden-
drocytes [14] or are restricted to a glial lineage [15]. We suggest that
the more the surviving stem cells in the host tissue, the higher the
possibility for these stem cells to keep undifferentiated and thus to
secrete more cytokines and growth factors. As shown in our human
cytokine array results, although large amount of human NAP-2,
NT-3, and VEGF R3 was secreted in the transected spinal cord of
the stem cell (undifferentiated), NCM-3 (differentiated) and NCM-6
(differentiated) days groups, the expressions of human bFGF and
GITR in the stem cell group were much higher than those in the
other three groups (control, NCM-3 and NCM-6 days) (Fig 6D).
Therefore, the mechanism underlying the promotive effect on the
regeneration of severed corticospinal axons after the transplantation
Figure 2. Tracing of the corticospinal tract in the injured spinal cord. Biotinylated dextran amine (BDA) was injected into the bilateral
sensorimotor cortex at 16 weeks post-transection. The control group exhibits a few BDA dots in the rostral stump of the injury (A) but not in the
caudal stump (B). BDA-positive fibers with brown dots are visible in the rostral and caudal stumps of the lesioned spinal cord in the three
transplanted groups (stem cell, NCM-3 and NCM-6 days) (C and D are from the rostral and caudal stumps of the stem cell group; E and F are from the
rostral and caudal stumps of the NCM-3 days group; G and H are from the rostral and caudal stumps of the NCM-6 days group). The brown dots
indicate the BDA-positive fibers. NCM: neuronal conditioned medium. Scale bar: 100 mm.
doi:10.1371/journal.pone.0003336.g002
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from the undifferentiated stem cells rather than the differentiation of
these cells into neuronal or glial cells. Similar conclusions have been
reported by Song et al [16] and Neuhuber et al [17]. They speculate
that transplanted bone marrow mesenchymal stem cells facilitate
recovery from spinal cord lesions by releasing brain natriuretic
peptide and other vasoactive factors that reduce edema, decrease
intracranial pressure, and improve cerebral perfusion [17,18].
Figure 3. Neurofilament-positive fibers around the lesion 4 months after transection. In A, D, G, and J, the left side is rostral.
Representative horizontal sections of the lesion show neurofilament-positive fibers (arrows) in the control group (A–C), stem cell group (D–F), NCM-3
days group (G–I), and NCM-6 days group (J–L). Neurofilament-positive fibers are scarce in the control group. The two right panels are magnified
images of the boxed areas. Scale bars: 100 mm in B, C, E, F, H, I, K, L; 1 mm in A, D, G, J. The number (M) and total length (N) of neurofilament-positive
(NF
+) fibers in the transection site of the spinal cord significantly increase in the stem cell group and the groups of NCM-3 days and NCM-6 days,
compared with the control group, 4 months after transplantation. * Significant difference at p,0.05 compared with the control group. # Significant
difference at p,0.05 compared with the NCM-3 and NCM-6 days groups, respectively.
doi:10.1371/journal.pone.0003336.g003
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and functional outcomes in chronic stages of injury [19]. Neuronal
stem cells constitutively secret NT-3 and promote axonal growth
after spinal cord injury [18].
Neovascularization or angiogenesis is necessary for the remod-
eling ofinjured tissue.OneofthemajorangiogenicfactorsisVEGF,
which binds to the VEGF Receptor. Signal transduction mediated
by this receptorserves various functions incell proliferation,survival
[20,21], and neovascularization [22,23]. In response to anoxia, an
increase in VEGF concentration and an altered pattern in the
expression of VEGF receptor have been found in hippocampal
neurons in vitro and in mouse brain, kidney, testis, lung, heart, and
liver in vivo [24–26]. In addition, VEGF is expressed in cultivated
adult neural stem cells isolated from the regions of the rat brain with
known spontaneous neurogenesis [27].
Previous research shows that the treatment with bFGFsignificantly
reduces injury zone and protects the survival of motor neurons after
spinal cord injury [28–30]. However, the underlying mechanisms of
bFGF for functional recovery are still not identified yet.
In accordance with the up-regulated cytokines and growth
factors, the functional outcomes of the stem cell group are
significantly better than those of NCM-3 and NCM-6 day groups
in the early stage after spinal cord injury. We speculate that some
other cytokines and growth factors beyond the 174 we assessed
may also stimulate the regeneration of the injured spinal cord.
More interestingly, the cytokines released from transplanted
HUMSCs in the injured spinal cord are different from those in
the liver with fibrosis (data not shown). We suggest that this
heterogeneity in the release of cytokines and growth factors
depends on the pathological microenvironments.
Fibrin glue used in this study is a biocompatible tissue adhesive
that has been safely applied to the research paradigm of spinal
cord injury in rodents and nonhuman primates to facilitate wound
healing [31–33]. We applied equal amount and concentration of
fibrin glue to the transection site in all 4 groups, including the
transected control group that received no stem cell transplanta-
tion. Therefore, the differences observed among these 4 groups are
unlikely a result of fibrin glue usage.
Figure 4. Changes in the distribution of neuroglia in spinal cords after HUMSC transplantation. In A, D, G, and J, the left side is rostral.
Representative horizontal sections of the lesion show anti-GFAP (to label astrocytes) (A–F) and anti-ED1 (to label microglia) (G–L) immunostaining4
months after transection. In the control group, the lesion is bordered by GFAP-positive glial scar (A–C) and in infiltrated by ED1-positive cells (G–I,
arrows). In the stem cell group, the glial scar is less dense (D–F, arrows) and ED1-positive microglia are fewer (J–L, arrows) than those in the control
group. The two right panels are magnified images of the left boxed areas. Scale bars: 1 mm in A, D, G, J ; 100 mmi nB ,C ,E ,F ,H ,I ,K ,L .
doi:10.1371/journal.pone.0003336.g004
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important role in CNS injury. Experimentally and clinically,
CNS damage is followed by an acute and a prolonged
inflammatory response characterized by the production of
inflammatory cytokines, infiltration of leukocytes and monocytes
in the injured area, as well as the activation of resident glial cells,
events that may contribute to secondary CNS injury [34–36].
Microglial cells are the main effectors of the innate response after
Figure 5. Photomicrographs showing the survival of HUMSCs in rat spinal cords 4 months after transplantation. In A, E, and H, the left
side is rostral. Representative horizontal sections show the nuclei of HUMSCs labeled by anti-human specific nuclear antigen in the rostral and caudal
stumps of the spinal cord in the stem cell group (A–D), NCM-3 days group (E–G), and NCM-6 days group (H–J). The HUMSCs are microinjected into
the transected spinal cords of rats. These cells survive in the spinal cord for 4 months after transplantation. HUMSCs are still evident about 3 mm
caudal to the transection in the stem cell group (D). Arrows indicate positively stained cell bodies. The two right panels are magnified images of the
boxed areas. The broken line indicates the transection. Scale bars: 1 mm in A, E, H; 100 mm in B–D, F, G, I, J. Line drawings of the rat spinal cord
demonstrate the extent of HUMSC migration 16 weeks after implantation in the stem cell group (K), NCM-3 days group (L), and NCM-6 days group
(M). In all images, the left side is rostral. Sections a, b, c, d, and e represent every other section of the spinal cord at intervals of 30 mm. N: cells labeled
by the anti-human specific nuclear antigen. Scale bar: 500 mm in K–M.
doi:10.1371/journal.pone.0003336.g005
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beneficial or detrimental effects on adjacent damaged neurons
remains controversial [37,38]. There is substantial evidence
demonstrating that activated microglia have the potential of
releasing cytotoxic factors including nitric oxide, reactive oxygen
species, and toxic prostanoids [39], as well as pro-inflammatory
cytokines such as tumor necrosis factor-a (TNF-a) or interleukin-
1b (IL-1b), which can decrease neuronal functions and promote
neurotoxicity [40–43]. In addition, attenuation of brain inflam-
matory response and microglial activation results in neuroprotec-
tion in various models of neurodegeneration [44–47]. On the
other hand, there is increasing evidence suggesting a neuropro-
tective role for microglia in several pathological conditions of the
CNS [48–50]. Exogenous application of microglia protects against
ischemic injury [51–53] and oxygen-glucose deprivation [49],
although its underlying molecular mechanisms have so far
remained unclear.
After spinal cord injury, astrocytes become hypertrophic,
proliferative, and up-regulated in expressing GFAP, and finally
form a dense network of glial processes at the lesion site that poses
a major physical impediment to regeneration [54]. Astroglial scar
formation also inhibits axonal regeneration chemically by
Figure 6. Characterization of HUMSCs in the injured spinal cord and behavioral recovery after HUMSC transplantation. Four months
after HUMSC transplantation, the immunostaining of anti-human specific nuclear antigen (blue) in the lesion does not co-localize with that of anti-
neurofilament (brown) (A), anti-GFAP (brown) (B), or anti-MBP (brown) (C), indicating that the majority of the implanted HUMSCs have not
differentiated into nerve cells, astrocytes, or oligodendrocytes. Scale bar: 50 mm. The relative expression levels of 174 human cytokines are quantified
by densitometry (D). The relative intensity of human NAP-2, NT-3, and VEGF R3 are significantly increased in the rat spinal cord of the stem cell, NCM-
3, and NCM-6 days groups compared with the control group (* p,0.05). The expression of human bFGF and GITR in the stem cell group are higher
than those in the control, NCM-3, and NCM-6 days groups (
# p,0.05). (E) The open-field locomotion of rats in different treatment groups is analyzed
by the Basso-Beattie-Bresnahan (BBB) Locomotor Rating Scale. The time course of recovery shows treatment-induced benefits start to become
apparent at 3 weeks after surgery. The stem cell group shows a statistically significant difference from the NCM-3 and NCM-6 days groups in the
seventh week. * indicates a statistical difference between the control group and the three implanted groups (stem cell, NCM-3 and NCM-6 days). #
indicates a statistical difference between the stem cell and NCM-3 and NCM-6 days groups. ¤ Control group & Stem cell group m NCM-3 days. N
NCM-6 days. (p,0.05 two-way ANOVA followed by LSD test).
doi:10.1371/journal.pone.0003336.g006
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proteoglycans [55–57]. Degradation of chondroitin sulphate
proteoglycans by chondroitinases has been demonstrated to
improve functional recovery after brain and spinal cord injuries
[58–61]. Therefore, it is important to regulate astroglial
proliferation and scar formation to create a favorable environment
for axonal regeneration.
Our study shows that implanted HUMSCs can modulate the
activities of microglia and reactive astrocytes, possibly by releasing
certain cytokines, in the injured spinal cord. This is evidenced by
the decreased number of microglia and reduced astroglial scarring
in the lesion after HUMSCs transplantation (Fig. 4). Similar
reports have shown that transplantation of mesechymal stem cells
modulates the activation of macrophages or microglia and
improves motor function in spinal cord-injured rats [62].
Mesenchymal stem cells have been intensively studied for their
potential use in reparative strategies for neurodegenerative
diseases and traumatic injuries. Transplantation of mesenchymal
stem cells obtained from rat bone marrow significantly improves
the recovery of motor function after spinal cord injury [63].
Similar improvements in motor function were found in spinal
cord-injured rats receiving human mesenchymal stem cells
obtained from adult bone marrow [64]. In our study, the BBB
locomotor score of the stem cell group reached the maximum
around 7, while the score of the control group consistently
remained lower than 2 throughout the entire period of 16 weeks.
As demonstrated in our results, such an improvement of motor
function after HUMSCs transplantation is associated with
abundant neurofilament-positive fibers and regenerative cortico-
spinal axons, reduced microglia infiltration and glial scar
formation, and increased expression of cytokines and growth
factors around the lesion.
Conclusion
Our study demonstrates that transplantation of HUMSCs from
Wharton’s jelly of the umbilical cord is beneficial to wound healing
and locomotor recovery after spinal cord injury in rats. Additional
research on the functional roles of HUMSCs after transplantation
may lead to novel approaches in the future to repairing injured
spinal cord.
Materials and Methods
Preparation of human umbilical mesenchymal stem cells
(HUMSCs)
This experiment was approved by the Research Ethics
Committee at the Taipei Veterans General Hospital. With the
written consent of the parents, fresh human umbilical cords were
obtained after birth and collected in Hanks’ Balanced Salt
Solution (HBSS) (Gibco, 14185-052, USA) at 4uC. Following
disinfection in 75% ethanol for 30 sec, the umbilical cord vessels
were cleared off while still in HBSS. The mesenchymal tissue (in
Wharton’s jelly) was then diced into cubes of about 0.5 cm
3 and
centrifuged at 250 g for 5 min. Following removal of the
supernatant fraction, the precipitate (mesenchymal tissue) was
washed with serum-free DMEM (Gibco, 12100-046) and centri-
fuged at 250 g for 5 min. Following aspiration of the supernatant
fraction, the precipitate (mesenchymal tissue) was treated with
collagenase at 37uC for 18 hours, washed, and further digested
with 2.5% trypsin (Gibco 15090-046) at 37uC for 30 min. FBS
(Hyclone, SH30071.03, USA) was then added to the mesenchymal
tissue to stop trypsinization. The dissociated mesenchymal cells
were further dispersed in 10% FBS-DMEM and counted under a
microscope with the aid of a hemocytometer. The mesenchymal
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nitrogen for later use.
Preparation of neuronal conditioned medium (NCM)
Sprague-Dawley rats at the age of postnatal day 7 were
anaesthetized by intraperitoneal injection of overdose pentobarbital
(150 mg/kg body weight). The brain was removed, placed in Ca
2+/
Mg
2+ free buffer (Gibco, 14185-052), and centrifuged at 900 rpm
for 5 minutes. Following removal of the supernatant fraction, 10%
FBS-DMEM was added to the precipitate (brain tissue). The brain
tissue suspension was triturated 15 times for dispersal into single
cells. The cells were suspended in 10% FBS-DMEM and incubated
at 37uCi n5 %C O 2 and 95% O2. In order to inhibit the growth of
glial cells, 2 mM AraC (Sigma, c-6645) was added on the next day.
On the 5th day of culture, the culture medium, i.e. NCM, was
collected to be used for the culture of HUMSCs. The HUMSCs
were cultured in NCM alone, which was replaced every other day.
Animal groups
Female Sprague-Dawley rats (250–300 g body weight) were
obtained from the Animal Center of National Yang-Ming
University, Taiwan. The Animal Research Committee of the
College of Medicine, National Yang-Ming University, approved the
study in accordance with the guidelines for the care and use of
laboratory animals.
For the different treatments, the rats were divided into four
experimental groups: (1) control group, with spinal cord transection
and fibrin glue-only in the lesion site (n=8); (2) transection, with
HUMSCs and fibrin-glue in the lesion site (referred to as stem cell
group;n=13);(3)transection,withHUMSCstreated withNCMfor
3 days and fibrin-glue in the lesion site (referred to as NCM-3 days
group; n=9); (4) transection, with HUMSCs treated with NCM for
6 days and fibrin-glue in the lesion site (referred to as NCM-6 days
group; n=8). NCM-treated or untreated HUMSCs were also
implanted in the rostral and caudal stumps of the transected spinal
cord in animals receiving HUMSC transplantation.
Spinal cord transection and HUMSC grafting
Adult female Sprague-Dawley rats were anesthetized with
halothane. After a laminectomy at the 7th–9th thoracic vertebral
levels, the dura was opened, and the spinal cord was completely
transected using a surgical blade. The severed ends of the cord
typically retracted about 1–2 mm. The rostral and caudal stumps
were lifted to ensure complete transection. Thereafter, 10
5 HUMSCs
were drawn into a glass pipette with a tip diameter of 150–200 mm
mounted onto a 5 ml Hamilton syringe (Hamilton, Reno, NV)
attached to a micromanipulator. The cells were deposited into two
injection sites at the rostral and the caudal stumps, 2 mm from the
lesion and 500 mm lateral to the midline, at a depth of 1000 mm. A
volumeof5 ml containing 10
5HUMSCsin phosphate buffered saline
(PBS) was grafted into each site (injection rate: 1 ml/min). Next, 10
5
HUMSCs in fibrin glue were implanted into the 1–2 mm gap to fill
the lesion site in the severed spinal cords. The treatments are
illustrated in Fig. 1. After surgery, rats were placed in temperature
and humidity controlled incubation chambers until they awoke. They
were then transferred to the cages, and bladder evacuation was
applied daily. Antibiotics (sodium ampicillin, 80 mg/kg body weight)
were injected daily into the rats for a week. The rats were maintained
under post-operative care for 16 weeks.
Assessment of motor function recovery
The Basso-Beattie-Bresnahan Locomotor Rating Scale was used
to assess locomotor recovery in an open field [65] by two observers
blinded to the animals’ identity. Before testing, bladders were
expressed, because spontaneous bladder contraction often accom-
panies hind-limb activity. The rats were placed in an open field
and were observed for 5 min. During testing, the activity of
animals was also video-monitored.
The histological study of spinal cords
Fixation and sectioning. The rats were perfused with
fixative (4% paraformaldehyde and 7.5% picric acid in 0.1 M
phosphate buffer (PB) 4 months after surgery. The spinal cord was
taken out and immersed in the same fixative at 4uC for 24 hours
and then switched to PB containing 30% sucrose before
cryosectioning. Successive sections of the spinal cord tissues were
sliced at a thickness of 30 mm by using a cryo-microtome and
adhered onto gelatin-pretreated slides.
Immunohistochemistry
Immunohistochemistry was performed by using primary
antibodies against 60 kD neurofilament (Chemicon,1:500), GFAP
(to label astrocytes; Chemicon, 1:1000), ED1 (alternated name
CD68 to label microglia; Chemicon, 1:500) and human specific
nuclear antigen (to label cells of human origin; Chemicon, 1:25), as
well as secondary antibodies (biotin-conjugated goat anti-rabbit-
IgG, 1:300 diluted, Sigma and biotin-conjugated goat anti-mouse-
IgG, 1:300 diluted, Sigma), followed by avidin-biotin-horseradish
peroxidase complex (ABC KIT, Vector Laboratories, PK-4000)
and 3,39-diaminobenzidine (5 mg in 3.5 ml 30% H2O2 and 10 ml
50 mM Tris Buffer). Tissue sections were dehydrated and
coverslipped with Permount. Pathological changes and quantifi-
cation of the nerve fibers in the transection site of the spinal cord
were observed under an optical microscope and analyzed by
ImagePro software.
Assessment of HUMSC differentiation
For the assessment of the possible differentiation of HUMSCs
into subpopulations of neurons, astrocytes, or oligodendrocytes, we
applied double staining for human-specific nuclear antigen [66]
and neurofilament, GFAP, and MBP, respectively.
Spinal cord sections were treated with a blocking solution for
30 min in order to prevent nonspecific antibody-antigen binding.
The sections were then reacted with primary antibodies against
60 kD neurofilament (Chemicon, 1:500), GFAP (Chemicon,
1:1000), or MBP (Chemicon, 1:500) at 4uC for 18 hours, washed
with 0.1 M PBS, reacted with secondary antibodies (alkaline
phosphatase-conjugated goat anti-mouse-IgG for human nuclei,
1:50; biotin-conjugated goat anti-mouse-IgG, 1:200, or biotin-
conjugated goat anti-rabbit-IgG, 1:200) at room temperature for
1 hour. After the chromogenic reaction, the sections were
coverslipped and observed under a microscope.
Anterograde tracing of the corticospinal tract
For axon tract tracing, rats received ten stereotaxic injections of
10% biotinylated dextran amine (BDA, MW=10,000, D-1956,
10% in 0.01 M PBS, Molecular Probes, Eugene) in the
sensorimotor cortex 16 weeks after the transection injury. For
each injection, 0.4 ml BDA was delivered over a period of 2 min
by using a glass pipette. These BDA-injected rats were sacrificed
and transcardially perfused with 4% paraformaldehyde (in 0.1 M
PB, pH 7.4) 14 days after the injection. The spinal cord and brain
were removed and postfixed overnight in the same fixative at 4uC.
The spinal cords were cryoprotected in 30% sucrose in PB (0.1 M,
pH 7.4) for at least 24 hours, frozen in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA), and cut into 30-mm-
HUMSCs for Spinal Cord Injury
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HRP (ABC Elite; Vector Laboratories), followed by a diamino-
benzidine HRP reaction for the visualization of the BDA tracer.
Human protein cytokine array
In order to elucidate which human cytokines were involved in
the repair of spinal cord injury, a human protein cytokine kit
(RayBioH Human Cytokine Antibody Array C Series 2000,
RayBiotech, Inc. AAH-CYT-2000) was used for the human
protein cytokine assay 3 weeks after injury. The rat spinal cord,
1.5 cm in length and centered over the lesion, was homogenated
and centrifuged in 16 cell lysis buffer at 1,500 g to remove cell
debris. The membranes included in the human protein cytokine
array kit were blocked with a blocking buffer, and then 1 ml of
sample supernatant was individually added and incubated at room
temperature for 2 h. The membranes were then analyzed
according to the manufacturer’s instructions.
Statistical analyses
All data were presented as means6standard error (SE). One-
way or two-way ANOVA were used to compare all means, and
Least Significant Difference (LSD) was used for the posteriori test.
In all statistical analyses p,0.05 was considered significant.
Supporting Information
Video S1 The locomotion behavior of the control group at week
16 after transection of the spinal cord.
Found at: doi:10.1371/journal.pone.0003336.s001 (0.87 MB
MPG)
Video S2 The locomotion behavior of the stem cell group at
week 16 after transection of the spinal cord.
Found at: doi:10.1371/journal.pone.0003336.s002 (6.28 MB
MPG)
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